| Comprehensive Online Oncology Database | |
|
Marketed Drug Sales Table
Note: Report links have been disabled for this sample screen.
| SUBSCRIBER SEARCH | ||||||||
|
|
REPORT FORMAT Marketed Drug Sales Table Note: Report links have been disabled for this sample screen. |
|
|||||||||||||
| 1-949-830-0448 | info@newmedinc.com | ||||||||||||||
| Developer | Brand Name • Generic Name | Sales Year | US Sales (US $) | Overseas Sales (US $) | Total Sales (US $) | Current as of |
|
Amgen
| Neulasta • Neupopeg • Pegfilgrastim • PEG(r-metHuG-CSF) | 2005 | 1,900,000,000 | 388,000,000 | 2,288,000,000 | November 26, 2007 |
|
Amgen
| Vectibix • Panitumumab | 2006 | 39,000,000 | 39,000,000 | November 25, 2007 | |
|
Bayer
| Nexavar • Sorafenib tosylate | 2006 | 165,000,000 | November 20, 2007 | ||
|
Bristol-Myers Squibb
| Sprycel • Dasatinib | 2006 | 22,000,000 | 3,000,000 | 25,000,000 | November 29, 2007 |
| HOME | NEW MEDICINE | SITE MAP |
NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM